- Affirmative Recovery
- Alternative Dispute Resolution
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Litigation Support Services
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Wealth Planning, Administration, and Disputes
-
July 8, 2020Lauren Coppola and Jamie Kurtz Named Law360 Rising Stars
-
July 8, 2020Robins Kaplan Receives High Ranks from Managing Intellectual Property
-
July 7, 2020New York Law Journal Recognizes Kellie Lerner as a Distinguished Leader
-
July 21, 2020Discovering a Hidden Revenue Stream: Recoveries from Antitrust Class Action Settlements in Economic Downturn
-
August 18, 2020Discovering a Hidden Revenue Stream: Recoveries from Antitrust Class Action Settlements in Economic Downturn
-
September 10, 2020Volunteer Lawyers Network Riverfront Celebration 2020
-
Summer 2020The Brave New World of Virtual Notarization
-
Summer 2020What Could be the Harm? Minnesota's Harmless Error Statute
-
Summer 2020What's a Fiduciary To Do? Considerations for Periods of Uncertainty
Elmiron-Related Injuries: Maculopathy
You must read the following notice before sending an e-mail message to Robins Kaplan LLP.
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
How Can An Eye Doctor Tell If I Have Maculopathy?
During a comprehensive eye exam, an eye doctor (or, ophthalmologist) will perform a diagnostic procedure called a “dilated fundus exam.” First, the eye doctor gives the patient special eye drops that dilate the pupil of the eye. Then, the doctor uses an ophthalmoscope to view or take photographs of the “fundus” of the eye, which is the interior surface opposite the lens.
When a pupil is dilated, it opens wide, and allows an eye doctor to clearly see the back of the eye, where signs of eye disease that may lead to blindness can be identified. During this process, an eye doctor can clearly see the retina and other important parts of the eye. While viewing the retina, the doctor can identify signs of macular degeneration, such as yellow spots beneath the retina called “drusen” or dark clumps of pigment.
This video by the National Eye Institute, a division of the National Institutes of Health, shows what a doctor sees when the doctor performs a dilated fundus exam:
While it is estimated that more than 10 million Americans have a form of macular degeneration, authors of several peer-reviewed journal articles investigating a link between Elmiron use and macular degeneration have observed through dilated fundus imaging that certain Elmiron users may show a “distinctive clinical phenotype” of “a unique pigmentary maculopathy.” That is to say, those who suffer from Elmiron-related vision loss may have a unique and distinctive injury that can be attributed to Elmiron.
Before making any changes to your medication or treatment, please discuss with your healthcare providers first.
How Robins Kaplan Law Firm Can Help With Your Elmiron Lawsuit
Our nationally recognized mass tort attorneys assist clients who are seriously injured by dangerous and defective products, and we are available to evaluate your potential claim against the manufacturers of Elmiron.
Robins Kaplan’s medical and pharmaceutical attorneys have the experience to take on big drug companies. Our team of attorneys, registered nurses, paralegals, and case assistants will thoroughly investigate your case by doing the following as needed:
- Upon commencement of legal representation, one of our attorneys, legal nurses or paralegals will call you and discuss your relevant medical history and prescription drug use.
- We will order and review your medical and pharmaceutical records, and we will determine if you took a potentially harmful drug, and we will evaluate whether that drug hurt you.
- Our pharmaceutical lawyers will compare the laws of your state with the timeline of events, including, key dates in your medical timeline and dates of certain acts or omissions by the medicine manufacturer, and we will plan the best litigation strategy for your case.
- We will investigate whether the drug manufacturer complied with FDA regulations and whether the manufacturer warned you about risks and side effects associated with the drug.
Throughout the entire process, our legal team will keep you informed about your case.
Diagnosed with Maculopathy After Taking Elmiron Pentosan Medication?
Contact us for a free and confidential evaluation today. To get started, call 1.800.610.7562 or fill out our online contact form above.
1 https://www.macular.org/what-macular-degeneration.
2 Hanif AM, Jain N. Clinical Pearls for a New Condition: Pentosan polysulfate therapy, a common treatment for interstitial cystitis, has been associated with a maculopathy. Review of Ophthalmolgy. 2019 July 10.
3 Pearce WA, Chen R, Jain N. Pigmentary Maculopathy Associated with Chronic Exposure to Pentosan Polysulfate Sodium. Ophthalmology. 2018 Nov;125(11):1793-1802.
RELATED PROFESSIONALS
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.